Comprehensive pan-cancer analysis reveals ubiquitin-conjugating enzyme 2T as a potential biomarker for prognosis and cancer immunity

Abstract Ubiquitin-conjugating enzyme 2T (UBE2T) constitutes a critical component of the ubiquitin-proteasome system and is involved in tumorigenesis. The UBE2T gene has been extensively characterized. In the present study, comprehensive analyses using various databases and R-based tools revealed elevated UBE2T expression across multiple tumor types, where its upregulation was shown to be associated with poor clinical outcomes and prognosis. Gene variation analysis identified ‘amplification’ as the predominant alteration in the UBE2T gene, followed by mutations; data from the GSCALite database